This study focuses on patients with sepsis, a serious condition that occurs when the body’s response to infection causes injury to its own tissues. The research aims to determine which patients with sepsis would benefit most from treatment with corticosteroid medications. The study will test two medications: hydrocortisone combined with fludrocortisone, comparing them against placebo in patients who are being treated in the intensive care unit due to suspected or proven infection.
The medications being studied belong to a group of drugs called corticosteroids, which help reduce inflammation in the body. Hydrocortisone hemisuccinate is given through a vein, while fludrocortisone is taken as a tablet. Some patients will receive the actual medications, while others will receive placebo versions that look the same but contain no active ingredients.
The study will track how patients respond to treatment over 90 days, focusing on their survival and recovery from organ problems. Specifically, the researchers will monitor whether patients still need breathing machines, blood pressure medications, or kidney support. The study will also follow patients’ progress for up to 6 months after starting treatment to understand the long-term effects of these medications.



France